ACADIA Pharmaceuticals (ACAD) Short Interest Ratio & Short Volume → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free ACAD Stock Alerts $16.95 -0.12 (-0.70%) (As of 11:40 AM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media ACADIA Pharmaceuticals Short Interest DataCurrent Short Volume11,200,000 sharesPrevious Short Volume10,630,000 sharesChange Vs. Previous Month+5.36%Dollar Volume Sold Short$207.09 millionShort Interest Ratio / Days to Cover6.1Last Record DateMarch 31, 2024Outstanding Shares164,770,000 sharesPercentage of Shares Shorted6.80%Today's Trading Volume263,835 sharesAverage Trading Volume1,740,594 sharesToday's Volume Vs. Average15% Short Selling ACADIA Pharmaceuticals ? Sign up to receive the latest short interest report for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatACAD Short Interest Over TimeACAD Days to Cover Over TimeACAD Percentage of Float Shorted Over Time Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story ACADIA Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202411,200,000 shares $207.09 million +5.4%N/A6.1 $18.49 3/15/202410,630,000 shares $196.44 million -1.7%N/A5.8 $18.48 2/29/202410,810,000 shares $251.22 million +14.8%N/A5.5 $23.24 2/15/20249,420,000 shares $237.20 million +22.7%N/A5.3 $25.18 1/31/20247,680,000 shares $198.99 million -5.3%N/A4.4 $25.91 1/15/20248,110,000 shares $233.00 million +2.5%N/A4.6 $28.73 Get the Latest News and Ratings for ACAD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 12/31/20237,910,000 shares $247.66 million +2.9%N/A4.6 $31.31 12/15/20237,690,000 shares $219.78 million -0.5%N/A4 $28.58 11/30/20237,730,000 shares $172.22 million -0.8%N/A4.8 $22.28 11/15/20237,790,000 shares $175.82 million +3.3%N/A5 $22.57 10/31/20237,540,000 shares $170.18 million +4.0%N/A4.7 $22.57 10/15/20237,250,000 shares $167.77 million -19.1%N/A4.4 $23.14 9/30/20238,960,000 shares $186.73 million -16.3%N/A4.8 $20.84 9/15/202310,700,000 shares $264.50 million +5.1%N/A6.6 $24.72 8/31/202310,180,000 shares $275.06 million +4.2%N/A6.5 $27.02 8/15/20239,770,000 shares $280.59 million +10.3%N/A6 $28.72 7/31/20238,860,000 shares $259.07 million +0.9%N/A5.3 $29.24 7/15/20238,780,000 shares $282.54 million +5.0%N/A5.7 $32.18 6/30/20238,360,000 shares $200.22 million -10.9%N/A6.3 $23.95 6/15/20239,380,000 shares $228.78 million -6.6%N/A7 $24.39 5/31/202310,040,000 shares $235.94 million +0.7%N/A6.5 $23.50 5/15/20239,970,000 shares $220.54 million +3.3%N/A6.1 $22.12 4/30/20239,650,000 shares $205.83 million +0.4%6.0%6.1 $21.33 4/15/20239,610,000 shares $172.88 million +17.5%6.0%6 $17.99 3/31/20238,180,000 shares $153.95 million -3.8%5.1%5.2 $18.82 3/15/20238,500,000 shares $168.73 million +5.7%5.3%5.6 $19.85 2/28/20238,040,000 shares $166.35 million -0.3%5.0%6.3 $20.69 2/15/20238,060,000 shares $152.90 million -0.5%5.1%7.1 $18.97 1/31/20238,100,000 shares $154.14 million +1.1%5.1%6.9 $19.03 1/15/20238,010,000 shares $147.38 million -4.5%5.0%6.5 $18.40 12/30/20228,390,000 shares $133.57 million -3.6%5.3%6.8 $15.92 12/15/20228,700,000 shares $131.11 million -10.0%5.5%6.6 $15.07 11/30/20229,670,000 shares $150.66 million +7.0%6.1%7 $15.58 11/15/20229,040,000 shares $141.84 million -13.4%5.7%6.2 $15.69 10/31/202210,440,000 shares $167.35 million +9.7%6.5%6.7 $16.03 10/15/20229,520,000 shares $149.65 million -1.7%6.0%6.1 $15.72 9/30/20229,680,000 shares $158.36 million +0.8%6.1%5.9 $16.36 9/15/20229,600,000 shares $175.39 million -3.7%6.0%5.4 $18.27 8/31/20229,970,000 shares $163.81 million -1.5%6.3%3.9 $16.43 8/15/202210,120,000 shares $167.99 million +4.7%6.4%3.9 $16.60Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story ACAD Short Interest - Frequently Asked Questions What is ACADIA Pharmaceuticals' current short interest? Short interest is the volume of ACADIA Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of March 31st, traders have sold 11,200,000 shares of ACAD short. Learn More on ACADIA Pharmaceuticals' current short interest. What is a good short interest ratio for ACADIA Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ACAD shares currently have a short interest ratio of 6.0. Learn More on ACADIA Pharmaceuticals's short interest ratio. Which institutional investors are shorting ACADIA Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of ACADIA Pharmaceuticals: Goldman Sachs Group Inc., GTS Securities LLC, Torno Capital LLC, Barclays PLC, Wolverine Trading LLC, Parallax Volatility Advisers L.P., Citadel Advisors LLC, Goldman Sachs Group Inc., Worth Venture Partners LLC, Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is ACADIA Pharmaceuticals' short interest increasing or decreasing? ACADIA Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 11,200,000 shares, an increase of 5.4% from the previous total of 10,630,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does ACADIA Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to ACADIA Pharmaceuticals: MoonLake Immunotherapeutics (16.21%), HUTCHMED (China) Limited (0.29%), MorphoSys AG (1.08%), Arrowhead Pharmaceuticals, Inc. (7.16%), Indivior PLC (0.13%), Janux Therapeutics, Inc. (11.58%), IDEAYA Biosciences, Inc. (14.29%), Amicus Therapeutics, Inc. (11.00%), Xenon Pharmaceuticals Inc. (3.66%), Evotec SE (0.02%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short ACADIA Pharmaceuticals stock? Short selling ACAD is an investing strategy that aims to generate trading profit from ACADIA Pharmaceuticals as its price is falling. ACAD shares are trading down $0.12 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against ACADIA Pharmaceuticals? A short squeeze for ACADIA Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ACAD, which in turn drives the price of the stock up even further. How often is ACADIA Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ACAD, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: MoonLake Immunotherapeutics Short Interest HUTCHMED Short Interest MorphoSys Short Interest Arrowhead Pharmaceuticals Short Interest Indivior Short Interest Janux Therapeutics Short Interest IDEAYA Biosciences Short Interest Amicus Therapeutics Short Interest Xenon Pharmaceuticals Short Interest Evotec Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ACAD) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIThe #1 Crypto for 2024InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent alert: open this for a huge profit potentialTimothy Sykes1970’s computer coder issues shocking A.I. warningTradeSmithTop 5 AI Stocks to Buy for 2024Market Moving Trends